دورية أكاديمية
أعرض في EDS

The role of EphA7 in different tumors.

التفاصيل البيبلوغرافية
العنوان: The role of EphA7 in different tumors.
المؤلفون: Chen X; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Yu D; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Zhou H; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China. zhouhy@lzu.edu.cn.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China. zhouhy@lzu.edu.cn.; Xigu District People's Hospital, Lanzhou, 730030, China. zhouhy@lzu.edu.cn., Zhang X; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Hu Y; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Zhang R; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Gao X; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Lin M; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Guo T; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China., Zhang K; Department of Orthopedics, Lanzhou University Second Hospital, 82 Cuiying Men, Lanzhou, 730030, China.; Gansu Key Laboratory of Bone and Joint Diseases, Lanzhou, 730030, China.; Xigu District People's Hospital, Lanzhou, 730030, China.
المصدر: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Jul; Vol. 24 (7), pp. 1274-1289. Date of Electronic Publication: 2022 Feb 02.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Country of Publication: Italy NLM ID: 101247119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1699-3055 (Electronic) Linking ISSN: 1699048X NLM ISO Abbreviation: Clin Transl Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: <2010- >: Milan : Springer Italia
Original Publication: Barcelona, Spain : Doyma, c2005-
مواضيع طبية MeSH: Neoplasms*/genetics , Receptor, EphA7*/genetics , Receptor, EphA7*/metabolism, Apoptosis ; Cell Proliferation ; Genes, Tumor Suppressor ; Humans ; Signal Transduction/physiology
مستخلص: Ephrin receptor A7 (EphA7) is a member of the Eph receptor family. It is widely involved in signal transduction between cells, regulates cell proliferation and differentiation, and participates in developing neural tubes and brain. In addition, EphA7 also has a dual role of tumor promoter and tumor suppressor. It can participate in cell proliferation, migration and apoptosis through various mechanisms, and affect tumor differentiation, staging and prognosis. EphA7 may be a potential diagnostic marker and tumor treatment target. This article reviews the effects of EphA7 on a variety of tumor biological processes and pathological characteristics, as well as specific effects and regulatory mechanisms.
(© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).)
References: Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. (PMID: 25651787)
Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91. (PMID: 810420533734139)
Wild CP. The global cancer burden: necessity is the mother of prevention. Nat Rev Cancer. 2019;19(3):123–4. (PMID: 30683893)
Can G, Mushani T, Rajhi BHA, Brant JM. The global burden of cancer pain. Semin Oncol Nurs. 2019;35(3):315–21. (PMID: 31076099)
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Global Cancer Statistics, et al. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. https://doi.org/10.3322/caac.21660 . (PMID: 10.3322/caac.2166033538338)
Hachisuga T. Aging and uterine serous carcinoma. Histol Histopathol. 2018;33(11):1125–33. (PMID: 29565096)
Lv M, Dong ZJ, Tong YX, Li T, Hei Y, Yang XJ, et al. Retrospective analysis of clinicopathological characteristics of lacrimal gland pleomorphic adenoma and mechanism of tumorigenesis by the imbalance between apoptosis and proliferation. Med Sci Monit. 2021;27:e929152. (PMID: 798681733737504)
Parveen A, Akash MS, Rehman K, Kyunn WW. Dual role of p21 in the progression of cancer and its treatment. Crit Rev Eukaryot Gene Expr. 2016;26(1):49–62. (PMID: 27278885)
de Oliveira SA, Borges R, Dos Santos Rosa D, de Souza ACS, Seabra AB, Baino F, et al. Strategies for cancer treatment based on photonic nanomedicine. Materials. 2021. https://doi.org/10.3390/ma14061435 . (PMID: 10.3390/ma14061435865820934885429)
Miller DR, Ingersoll MA, Teply BA, Lin MF. Targeting treatment options for castration-resistant prostate cancer. Am J Clin Exp Urol. 2021;9(1):101–20. (PMID: 801282633816699)
Wang X, Niu X, An N, Sun Y, Chen Z. Comparative efficacy and safety of immunotherapy alone and in combination with chemotherapy for advanced non-small cell lung cancer. Front oncol. 2021;11:611012. (PMID: 801371433816241)
Belete TM. The current status of gene therapy for the treatment of cancer. Biol Targets Ther. 2021;15:67–77.
Giorgio C, Zanotti I, Lodola A, Tognolini M. Ephrin or not? Six tough questions on Eph targeting. Expert Opin Ther Targets. 2020;24(5):403–15. (PMID: 32197575)
Hirai H, Maru Y, Hagiwara K, Nishida J, Takaku F. A novel putative tyrosine kinase receptor encoded by the Eph gene. Science. 1987;238(4834):1717–20. (PMID: 2825356)
Surawska H, Ma PC, Salgia R. The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev. 2004;15(6):419–33. (PMID: 15561600)
Ma X, Ma Z, Jiao X, Hejtmancik JF. Functional non-coding polymorphism in an EPHA2 promoter PAX2 binding site modifies expression and alters the MAPK and AKT pathways. Sci Rep. 2017;7(1):9992. (PMID: 557720328855599)
Poppe L, Rué L, Timmers M, Lenaerts A, Storm A, Callaerts-Vegh Z, et al. EphA4 loss improves social memory performance and alters dendritic spine morphology without changes in amyloid pathology in a mouse model of Alzheimer’s disease. Alz Res Ther. 2019;11(1):102.
Leonard CE, Baydyuk M, Stepler MA, Burton DA, Donoghue MJ. EphA7 isoforms differentially regulate cortical dendrite development. PLoS ONE. 2020;15(12):e0231561. (PMID: 771753033275600)
Rudno-Rudzińska J, Kielan W, Frejlich E, Kotulski K, Hap W, Kurnol K, et al. A review on Eph/ephrin, angiogenesis and lymphangiogenesis in gastric, colorectal and pancreatic cancers. Chin J Cancer Res. 2017;29(4):303–12. (PMID: 559281828947862)
Giaginis C, Tsoukalas N, Bournakis E, Alexandrou P, Kavantzas N, Patsouris E, et al. Ephrin (Eph) receptor A1, A4, A5 and A7 expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival. BMC Clin Pathol. 2014;14(1):8. (PMID: 423438724495444)
Cui Y, Wu BO, Flamini V, Evans BAJ, Zhou D, Jiang WG. Knockdown of EPHA1 Using CRISPR/CAS9 suppresses aggressive properties of ovarian cancer cells. Anticancer Res. 2017;37(8):4415–24. (PMID: 28739735)
Okuyama T, Sakamoto R, Kumagai K, Nishizawa M, Kimura T, Sugie T, et al. EPHA2 antisense RNA modulates EPHA2 mRNA levels in basal-like/triple-negative breast cancer cells. Biochimie. 2020;179:169–80. (PMID: 33022313)
Lu C, Shahzad MM, Wang H, Landen CN, Kim SW, Allen J, et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther. 2008;7(7):1098–103. (PMID: 18443431)
Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, et al. EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell. 2013;23(2):238–48. (PMID: 23410976)
Zhang X. The expression profile and prognostic values of EPHA family members in breast cancer. Front Oncol. 2021;11:619949. (PMID: 825042434221956)
Zhou S, Wang L, Guo S, Zhang Z, Wang J. EphA4 protein promotes invasion in clear cell renal cell carcinomas. Int J Clin Exp Pathol. 2017;10(12):11737–42. (PMID: 696608031966534)
Zhang R, Liu J, Zhang W, Hua L, Qian LT, Zhou SB. EphA5 knockdown enhances the invasion and migration ability of esophageal squamous cell carcinoma via epithelial-mesenchymal transition through activating Wnt/β-catenin pathway. Cancer cell Int. 2020. https://doi.org/10.1186/s12935-020-1101-x . (PMID: 10.1186/s12935-020-1101-x774537933372609)
Zhou D, Ren K, Wang J, Ren H, Yang W, Wang W, et al. Erythropoietin-producing hepatocellular A6 overexpression is a novel biomarker of poor prognosis in patients with breast cancer. Oncol Lett. 2018;15(4):5257–63. (PMID: 584074329552165)
Li S, Ma Y, Xie C, Wu Z, Kang Z, Fang Z, et al. EphA6 promotes angiogenesis and prostate cancer metastasis and is associated with human prostate cancer progression. Oncotarget. 2015;6(26):22587–97. (PMID: 467318426041887)
Wu X, Yan L, Liu Y, Xian W, Wang L, Ding X. MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7. PLoS ONE. 2017;12(6):e0175553. (PMID: 546782428604772)
Bai YQ, Zhang JY, Bai CY, Xu XE, Wu JY, Chen B, et al. Low EphA7 expression correlated with lymph node metastasis and poor prognosis of patients with esophageal squamous cell carcinoma. Acta Histochem Cytochem. 2015;48(3):75–81. (PMID: 449149726160986)
Wang GH, Ni K, Gu C, Huang J, Chen J, Wang XD, et al. EphA8 inhibits cell apoptosis via AKT signaling and is associated with poor prognosis in breast cancer. Oncol Rep. 2021. https://doi.org/10.3892/or.2021.8134 . (PMID: 10.3892/or.2021.8134867470534958110)
Wang Y, Zhou N, Li P, Wu H, Wang Q, Gao X, et al. EphA8 acts as an oncogene and contributes to poor prognosis in gastric cancer via regulation of ADAM10. J Cell Physiol. 2019;234(11):20408–19. (PMID: 31026069)
Peng J, Zhang D. Coexpression of EphA10 and Gli3 promotes breast cancer cell proliferation, invasion and migration. J Investig Med. 2021;69(6):1215–21. (PMID: 832740733990369)
Shin WS, Park MK, Lee YH, Kim KW, Lee H, Lee ST. The catalytically defective receptor protein tyrosine kinase EphA10 promotes tumorigenesis in pancreatic cancer cells. Cancer Sci. 2020;111(9):3292–302. (PMID: 746977532644283)
Teng L, Nakada M, Furuyama N, Sabit H, Furuta T, Hayashi Y, et al. Ligand-dependent EphB1 signaling suppresses glioma invasion and correlates with patient survival. Neuro Oncol. 2013;15(12):1710–20. (PMID: 382959524121831)
Bhatia S, Baig NA, Timofeeva O, Pasquale EB, Hirsch K, MacDonald TJ, et al. Knockdown of EphB1 receptor decreases medulloblastoma cell growth and migration and increases cellular radiosensitization. Oncotarget. 2015;6(11):8929–46. (PMID: 449619325879388)
Leung HW, Leung CON, Lau EY, Chung KPS, Mok EH, Lei MML, et al. EPHB2 activates β-Catenin to enhance cancer stem cell properties and drive sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2021;81(12):3229–40. (PMID: 33903122)
Yin J, Li Z, Ye L, Birkin E, Li L, Xu R, et al. EphB2 represents an independent prognostic marker in patients with gastric cancer and promotes tumour cell aggressiveness. J Cancer. 2020;11(10):2778–87. (PMID: 708624632226496)
Zhao K, He J, Wang YF, Jin SD, Fan Y, Fang N, et al. EZH2-mediated epigenetic suppression of EphB3 inhibits gastric cancer proliferation and metastasis by affecting E-cadherin and vimentin expression. Gene. 2019;686:118–24. (PMID: 30408551)
Li JJ, Sun ZJ, Yuan YM, Yin FF, Bian YG, Long LY, et al. EphB3 stimulates cell migration and metastasis in a kinase-dependent manner through Vav2-Rho GTPase axis in papillary thyroid cancer. J Biol Chem. 2017;292(3):1112–21. (PMID: 27986811)
Ding J, Yao Y, Huang G, Wang X, Yi J, Zhang N, et al. Targeting the EphB4 receptor tyrosine kinase sensitizes HER2-positive breast cancer cells to Lapatinib. Cancer Lett. 2020;475:53–64. (PMID: 32006616)
Ferguson BD, Liu R, Rolle CE, Tan YH, Krasnoperov V, Kanteti R, et al. The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS ONE. 2013;8(7):e67668. (PMID: 369962423844053)
Liu J, Xu B, Xu G, Zhang X, Yang X, Wang J. Reduced EphB6 protein in gastric carcinoma and associated lymph nodes suggests EphB6 as a gastric tumor and metastasis inhibitor. Cancer Biomark. 2017;19(3):241–8. (PMID: 28453458)
Dong Y, Pan J, Ni Y, Huang X, Chen X, Wang J. High expression of EphB6 protein in tongue squamous cell carcinoma is associated with a poor outcome. Int J Clin Exp Pathol. 2015;8(9):11428–33. (PMID: 463768626617870)
Holmberg J, Clarke DL, Frisén J. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature. 2000;408(6809):203–6. (PMID: 11089974)
Tu Y, Cai Q, Zhu X, Xu M. Down-regulation of HCP5 inhibits cell proliferation, migration, and invasion through regulating EPHA7 by competitively binding miR-101 in osteosarcoma. Braz J Med Biol Res. 2021;54(2):e9161. (PMID: 779813733439936)
Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, et al. Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome. PLoS ONE. 2011;6(9):e24426. (PMID: 317417021935409)
Lucero M, Thind J, Sandoval J, Senaati S, Jimenez B, Kandpal RP. Stem-like cells from invasive breast carcinoma cell line MDA-MB-231 express a distinct set of Eph receptors and ephrin ligands. Cancer Genomics Proteomics. 2020;17(6):729–38. (PMID: 767564933099474)
Liu M, Zhou K, Cao Y. MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer. Int J Mol Sci. 2016. https://doi.org/10.3390/ijms17101493 . (PMID: 10.3390/ijms17101493529768828036026)
Li R, Sun Y, Jiang A, Wu Y, Li C, Jin M, et al. Knockdown of ephrin receptor A7 suppresses the proliferation and metastasis of A549 human lung cancer cells. Mol Med Rep. 2016;13(4):3190–6. (PMID: 26936314)
Liu DC, Yang ZL. MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma. Diagn Cytopathol. 2013;41(3):199–205. (PMID: 21964981)
Zhang SJ, Zhang G, Zhao YF, Wu Y, Li J, Chai YX. Expression of EphA7 protein in primary hepatocellular carcinoma and its clinical significance. Zhonghua wai ke za zhi [Chin J Surg]. 2010;48(1):53–6.
Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, et al. Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression. Cell Death Dis. 2017;8(10):e3122. (PMID: 568267229022918)
Guan M, Xu C, Zhang F, Ye C. Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 2009;124(1):88–94. (PMID: 18821581)
Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, et al. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 2011;147(3):554–64. (PMID: 320837922036564)
López-Nieva P, Vaquero C, Fernández-Navarro P, González-Sánchez L, Villa-Morales M, Santos J, et al. EPHA7, a new target gene for 6q deletion in T-cell lymphoblastic lymphomas. Carcinogenesis. 2012;33(2):452–8. (PMID: 22114070)
Shaker OG, Ayeldeen G, Abdelhamid AM. Circulating microRNA-944 and its target gene EPHA7 as a potential biomarker for colorectal cancer. Arch Physiol Biochem. 2020. https://doi.org/10.1080/13813455.2020.1762658 . (PMID: 10.1080/13813455.2020.176265832421395)
Üçüncü M, Serilmez M, Sarı M, Bademler S, Karabulut S. The diagnostic significance of PDGF, EphA7, CCR5, and CCL5 levels in colorectal cancer. Biomolecules. 2019. https://doi.org/10.3390/biom9090464 . (PMID: 10.3390/biom9090464677073231505877)
Di W, Weinan X, Xin L, Zhiwei Y, Xinyue G, Jinxue T, et al. Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7. Cell Death Dis. 2019;10(7):514. (PMID: 660968531273190)
Herath NI, Spanevello MD, Doecke JD, Smith FM, Pouponnot C, Boyd AW. Complex expression patterns of Eph receptor tyrosine kinases and their ephrin ligands in colorectal carcinogenesis. Eur J Cancer. 2012;48(5):753–62. (PMID: 21852108)
Xiang C, Lv Y, Wei Y, Wei J, Miao S, Mao X, et al. Effect of EphA7 silencing on proliferation, invasion and apoptosis in human laryngeal cancer cell lines hep-2 and AMC-HN-8. Cell Physiol Biochem. 2015;36(2):435–45. (PMID: 25968442)
Liu HY, Chang J, Li GD, Zhang ZH, Tian J, Mu YS. MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer. Eur Rev Med Pharmacol Sci. 2020;24(11):6139–49. (PMID: 32572879)
Guo Y, Shi W, Fang R. miR-18a-5p promotes melanoma cell proliferation and inhibits apoptosis and autophagy by targeting EPHA7 signaling. Mol Med Rep. 2021;23(1):1. (PMID: 33169172)
Sun Y, Xu C, Wu Q, Zhang L, Wang P. Long noncoding RNA KCNQ1OT1 promotes proliferation, migration, and invasion in maxillary sinus squamous cell carcinoma by regulating miR-204/EphA7 axis. J Cell Biochem. 2020;121(4):2962–9. (PMID: 31709597)
Noberini R, Koolpe M, Peddibhotla S, Dahl R, Su Y, Cosford ND, et al. Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors. J Biol Chem. 2008;283(43):29461–72. (PMID: 257088718728010)
Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, et al. Δ(5)-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. Eur J Med Chem. 2015;103:312–24. (PMID: 26363867)
Kathawala RJ, Wei L, Anreddy N, Chen K, Patel A, Alqahtani S, et al. The small molecule tyrosine kinase inhibitor NVP-BHG712 antagonizes ABCC10-mediated paclitaxel resistance: a preclinical and pharmacokinetic study. Oncotarget. 2015;6(1):510–21. (PMID: 25402202)
Buckens OJ, El Hassouni B, Giovannetti E, Peters GJ. The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment. Expert Opin Investig Drugs. 2020;29(6):567–82. (PMID: 32348169)
Nagano K, Maeda Y, Kanasaki S, Watanabe T, Yamashita T, Inoue M, et al. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. J Control Release. 2014;189:72–9. (PMID: 24946238)
Ansuini H, Meola A, Gunes Z, Paradisi V, Pezzanera M, Acali S, et al. Anti-EphA2 antibodies with distinct in vitro properties have equal in vivo efficacy in pancreatic cancer. J Oncol. 2009;2009:951917. (PMID: 20130824)
Duggineni S, Mitra S, Lamberto I, Han X, Xu Y, An J, et al. Design and synthesis of potent bivalent peptide agonists targeting the EphA2 receptor. ACS Med Chem Lett. 2013;4(3):344–8. (PMID: 3807576)
Chrencik JE, Brooun A, Recht MI, Nicola G, Davis LK, Abagyan R, et al. Three-dimensional structure of the EphB2 receptor in complex with an antagonistic peptide reveals a novel mode of inhibition. J Biol Chem. 2007;282(50):36505–13. (PMID: 17897949)
Zhang Z, Wu HX, Lin WH, Wang ZX, Yang LP, Zeng ZL, et al. EPHA7 mutation as a predictive biomarker for immune checkpoint inhibitors in multiple cancers. BMC Med. 2021;19(1):26. (PMID: 785213533526018)
Chakraborty S, Varma AK. Crystal structure of clinically reported mutations Gly656Arg, Gly656Glu and Asp751His identified in the kinase domain of EphA7. Biochem Biophys Res Commun. 2021;568:62–7. (PMID: 34186436)
Yang X, Xu X, Zhu H, Wang M, Wang D. Organoid research in digestive system tumors. Oncol Lett. 2021;21(4):308. (PMID: 790558633732384)
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363–85. (PMID: 31184787)
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. (PMID: 31912902)
Giaginis C, Tsourouflis G, Zizi-Serbetzoglou A, Kouraklis G, Chatzopoulou E, Dimakopoulou K, et al. Clinical significance of ephrin (eph)-A1, -A2, -a4, -a5 and -a7 receptors in pancreatic ductal adenocarcinoma. Pathol Oncol Res POR. 2010;16(2):267–76. (PMID: 19949912)
Chalikonda G, Lee H, Sheik A, Huh YS. Targeting key transcriptional factor STAT3 in colorectal cancer. Mol Cell Biochem. 2021. https://doi.org/10.1007/s11010-021-04156-8 . (PMID: 10.1007/s11010-021-04156-833866491)
Lv J, Wang J, Shang X, Liu F, Guo S. Survival prediction in patients with colon adenocarcinoma via multi-omics data integration using a deep learning algorithm. 2020. Biosci Rep. https://doi.org/10.1042/BSR20201482 . (PMID: 10.1042/BSR20201482775384533258470)
Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, et al. Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene. 2005;24(36):5637–47. (PMID: 16007213)
Zhang B, Min S, Guo Q, Huang Y, Guo Y, Liang X, et al. 7SK acts as an anti-tumor factor in tongue squamous cell carcinoma. Front Genet. 2021;12:642969. (PMID: 804710733868377)
Liao Y, Wang F, Zhang Y, Cai H, Song F, Hou J. Silencing SHMT2 inhibits the progression of tongue squamous cell carcinoma through cell cycle regulation. Cancer Cell Int. 2021;21(1):220. (PMID: 805271733863325)
van Dijk BA, Brands MT, Geurts SM, Merkx MA, Roodenburg JL. Trends in oral cavity cancer incidence, mortality, survival and treatment in the Netherlands. Int J Cancer. 2016;139(3):574–83. (PMID: 27038013)
Li D, Xiang B, Ying XX, Ying XX, Dong H. Correlation analysis of EphA7 expression with clinico-pathological parameters and prognosis in tongue squamous cell carcinoma. Shanghai J Stomatol. 2014;23(5):575–9.
Theocharis S, Klijanienko J, Giaginis C, Alexandrou P, Patsouris E, Sastre-Garau X. Ephrin receptor (Eph) -A1, -A2, -A4 and -A7 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. Pathol Oncol Res POR. 2014;20(2):277–84. (PMID: 24022400)
Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–68. (PMID: 677727131560378)
Wang G, Li Q, Li C, Duan G, Sang H, Dong H, et al. Knockdown of PNO1 inhibits esophageal cancer progression. Oncol Rep. 2021. https://doi.org/10.3892/or.2021.8036 . (PMID: 10.3892/or.2021.8036867470534958110)
Tan X, Ren S, Fu MZ, Ren S, Yang C, Wu X, et al. microRNA-196b promotes esophageal squamous cell carcinogenesis and chemoradioresistance by inhibiting EPHA7, thereby restoring EPHA2 activity. Am J Cancer Res. 2021;11(7):3594–610. (PMID: 833286134354862)
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC, Lordick F. Gastric cancer. Lancet. 2020;396(10251):635–48. (PMID: 32861308)
Chen X, Sun X, Li X, Xu L, Yu W. LncRNA-HEIH is a novel diagnostic and predictive biomarker in gastric cancer. Genet Test Mol Biomarkers. 2021;25(4):284–92. (PMID: 33877891)
Wang J, Li G, Ma H, Bao Y, Wang X, Zhou H, et al. Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol. 2007;38(11):1649–56. (PMID: 17669470)
Yamada T, Yoshii T, Yasuda H, Okawa A, Sotome S. Dexamethasone regulates EphA5, a potential inhibitory factor with osteogenic capability of human bone marrow stromal cells. Stem Cells Int. 2016;2016:1301608. (PMID: 473696127057165)
Liu Z, Yan C, Xiao Y, Zhang W, Wang L, Li Q, et al. Expression and inhibitory effects of p53-upregulated modulator of apoptosis in gallbladder carcinoma. Oncol Lett. 2021;21(3):234. (PMID: 785668433613723)
Zhou J, Nie W, Yuan J, Zhang Z, Mi L, Wang C, et al. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration. Oncol Rep. 2021. https://doi.org/10.3892/or.2021.8042 . (PMID: 10.3892/or.2021.8042860041834726249)
Li Q, Zhang Q, Cheng X, Weng X, Chen M, Hu X, et al. Next-generation sequencing characterizes the landscape of somatic mutations and pathways in metastatic bile tract carcinoma. J Oncol. 2020;2020:3275315. (PMID: 748709832952556)
Han R, Yang H, Lu L, Lin L. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Sci Rep. 2021;11(1):8626. (PMID: 806039333883691)
Wang Y, Gao R, Li J, Tang S, Li S, Tong Q, et al. Downregulation of hsa_circ_0074854 suppresses the migration and invasion in hepatocellular carcinoma via interacting with HuR and via suppressing exosomes-mediated macrophage M2 polarization. Int J Nanomed. 2021;16:2803–18.
Chen YH, Huang YC, Yang SF, Yen HH, Tsai HD, Hsieh MC, et al. Pitavastatin and metformin synergistically activate apoptosis and autophagy in pancreatic cancer cells. Environ Toxicol. 2021. https://doi.org/10.1002/tox.23146 . (PMID: 10.1002/tox.2314634850538)
Jang HJ, Yang JH, Hong E, Jo E, Lee S, Lee S, et al. Chelidonine induces apoptosis via GADD45a-p53 regulation in human pancreatic cancer cells. Integr Cancer Ther. 2021. https://doi.org/10.1177/15347354211006191 . (PMID: 10.1177/15347354211006191807749033884928)
Xu L, Yang M, Zhao T, Jin H, Xu Z, Li M, et al. The polymorphism of CYP2E1 Rsa I/Pst I gene and susceptibility to respiratory system cancer: a systematic review and meta-analysis of 34 studies. Medicine (Baltimore). 2014;93(27):e178.
Hou W, Zhou X, Yi C, Zhu H. Immune check point inhibitors and immune-related adverse events in small cell lung cancer. Front Oncol. 2021;11:604227. (PMID: 801639233816235)
Peifer M, Fernández-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44(10):1104–10. (PMID: 491582222941188)
Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene. 2007;26(29):4243–52. (PMID: 275683417260020)
Tsuboi M, Mori H, Bunai T, Kageyama S, Suzuki M, Okudela K, et al. Secreted form of EphA7 in lung cancer. Int J Oncol. 2010;36(3):635–40. (PMID: 20126984)
Huang DN, Liu HW, Li ZD. Expression of lncRNA-ATB in laryngeal carcinoma and its relationship with prognosis. Eur Rev Med Pharmacol Sci. 2020;24(21):11148–53. (PMID: 33215432)
Albakova Z, Mangasarova Y, Sapozhnikov A. Heat shock proteins in lymphoma immunotherapy. Front Immunol. 2021;12:660085. (PMID: 801276333815422)
Jamil A, Mukkamalla SKR. Lymphoma. I: StatPearls. Treasure Island: StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
Nastoupil LJ. When to use targeted therapy for the treatment of follicular lymphoma. Curr Hematol Malig Rep. 2021;16(1):45–51. (PMID: 33797691)
Kaseb H, Tariq MA, Gupta G. Lymphoblastic lymphoma. I: StatPearls. Treasure Island: StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC; 2021.
Burkhardt B, Hermiston ML. Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities. Br J Haematol. 2019;185(6):1158–70. (PMID: 30809797)
Ostadrahimi S, Fayaz S, Parvizhamidi M, Abedi-Valugerdi M, Hassan M, Kadivar M, et al. Downregulation of miR-1266-5P, miR-185-5P and miR-30c-2 in prostatic cancer tissue and cell lines. Oncol Lett. 2018;15(5):8157–64. (PMID: 596284929849810)
Rachner TD, Kasimir-Bauer S, Goebel A, Erdmann K, Hoffmann O, Rauner M, et al. Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer. J Cancer Res Clin Oncol. 2021. https://doi.org/10.1007/s00432-021-03635-1 . (PMID: 10.1007/s00432-021-03635-1823646233884469)
Manso L, Mourón S, Tress M, Gómez-López G, Morente M, Ciruelos E, et al. Analysis of paired primary-metastatic hormone-receptor positive breast tumors (HRPBC) uncovers potential novel drivers of hormonal resistance. PLoS ONE. 2016;11(5):e0155840. (PMID: 487317427195705)
Rahimi S. Squamous cell carcinoma of skin: a brief review. Clin Ter. 2013;164(2):143–7. (PMID: 23698209)
Ombredane AS, de Andrade LR, Bonadio RS, Pinheiro WO, de Azevedo RB, Joanitti GA. Melittin sensitizes skin squamous carcinoma cells to 5-fluorouracil by affecting cell proliferation and survival. Exp Dermatol. 2021. https://doi.org/10.1111/exd.14289 . (PMID: 10.1111/exd.1428933523510)
Anderson AN, McClanahan D, Jacobs J, Jeng S, Vigoda M, Blucher AS, et al. Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma. Cold Spring Harb Mol Case Stud. 2020. https://doi.org/10.1101/mcs.a005439 . (PMID: 10.1101/mcs.a005439747640932843430)
Gao G, Yao Z, Shen J, Liu Y. Identification of key miRNAs in the treatment of dabrafenib-resistant melanoma. Biomed Res Int. 2021;2021:5524486. (PMID: 804654633880366)
Gao C, Gao J, Zeng G, Yan H, Zheng J, Guo W. MicroRNA-629–5p promotes osteosarcoma proliferation and migration by targeting caveolin 1. Braz J Med Biol Res. 2021;54(6):e10474. (PMID: 805518633886809)
Wang Y, Liu N, Li MY, Du MF. Long non-coding RNA ZEB2-AS1 regulates osteosarcoma progression by acting as a molecular sponge of miR-107 to modulate SALL4 expression. Am J Transl Res. 2021;13(3):1140–54. (PMID: 801437933841645)
Zheng L, Wang J, Wei S, Zhao SX, Yuan WH, Zhou HY. Expression of EphA7 in osteosarcoma and its effect on proliferation, migration and apoptosis of osteosarcoma MG-63 cells. Chin J Cancer. 2019;29(3):171–7.
Zhao P, Li T, Wang Y, Wang Y, Gu Q, Li Z. LncRNA MYCNOS promotes glioblastoma cell proliferation by regulating miR-216b/FOXM1 axis. Metab Brain Dis. 2021. https://doi.org/10.1007/s11011-021-00729-0 . (PMID: 10.1007/s11011-021-00729-034460046)
Alexander BM, Cloughesy TF. Adult Glioblastoma. J Clin Oncol. 2017;35(21):2402–9. (PMID: 28640706)
Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, et al. Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer. 2008. https://doi.org/10.1186/1471-2407-8-79 . (PMID: 10.1186/1471-2407-8-79262536619099597)
Lou X, Cai Y, Zheng H, Zhang Y. MicroRNA-146b-5p/EPHA7 axis regulates cell invasion, metastasis, proliferation, and temozolomide-induced chemoresistance via regulation of IRAK4/TRAF6/NF-κB signaling pathway in aggressive pituitary adenoma. Histol Histopathol. 2021. https://doi.org/10.14670/HH-18-391 . (PMID: 10.14670/HH-18-39134746996)
Bhatti GK, Khullar N, Sidhu IS, Navik US, Reddy AP, Reddy PH, et al. Emerging role of non-coding RNA in health and disease. Metab Brain Dis. 2021. https://doi.org/10.1007/s11011-021-00739-y . (PMID: 10.1007/s11011-021-00739-y805849834309746)
de Gonzalo-Calvo D, Thum T. Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles. Eur Heart J. 2018;39(38):3552. (PMID: 30060047)
Romano G, Saviana M, Le P, Li H, Micalo L, Nigita G, et al. Non-coding RNA editing in cancer pathogenesis. Cancers. 2020. https://doi.org/10.3390/cancers12071845 . (PMID: 10.3390/cancers12071845776742033371419)
Du T, Gao Q, Zhao Y, Gao J, Li J, Wang L, et al. Long non-coding RNA LINC02474 affects metastasis and apoptosis of colorectal cancer by inhibiting the expression of GZMB. Front Oncol. 2021;11:651796. (PMID: 806304433898319)
Dong C, Wu J, Chen Y, Nie J, Chen C. Activation of PI3K/AKT/mTOR pathway causes drug resistance in breast cancer. Front Pharmacol. 2021;12:628690. (PMID: 800551433790792)
Kma L, Baruah TJ. The interplay of ROS and the PI3K/Akt pathway in autophagy regulation. Biotechnol Appl Biochem. 2021. https://doi.org/10.1002/bab.2104 . (PMID: 10.1002/bab.210433442914)
Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside. Semin Cancer Biol. 2019;59:125–32. (PMID: 31323288)
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275(5308):1943–7. (PMID: 9072974)
Mendes RD, Canté-Barrett K, Pieters R, Meijerink JP. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia. Haematologica. 2016;101(9):1010–7. (PMID: 506001727582570)
فهرسة مساهمة: Keywords: Diagnostic markers; Ephrin receptor A7 (EphA7); Mechanism; Prognosis; Therapeutic target; Tumor
المشرفين على المادة: EC 2.7.10.1 (Receptor, EphA7)
تواريخ الأحداث: Date Created: 20220203 Date Completed: 20220615 Latest Revision: 20220616
رمز التحديث: 20221213
DOI: 10.1007/s12094-022-02783-1
PMID: 35112312
قاعدة البيانات: MEDLINE
الوصف
تدمد:1699-3055
DOI:10.1007/s12094-022-02783-1